中国医院与生物医学产业十年来合作创新网络的社会网络分析。
Social network analysis of a decade-long collaborative innovation network between hospitals and the biomedical industry in China.
机构信息
Affiliated Xihu Hospital, Hangzhou Medical College, Hangzhou, 310000, China.
Department of Respiratory Disease, The 903Rd Hospital of PLA, Hangzhou, 310000, China.
出版信息
Sci Rep. 2024 May 18;14(1):11374. doi: 10.1038/s41598-024-62082-3.
Collaborative innovation between hospitals and biomedical enterprises is crucial for ensuring breakthroughs in their development. This study explores the structural characteristics and examines the main roles of associated key actors of collaborative innovation between hospitals and biomedical enterprises in China. Using the jointly owned patent data within the country's healthcare industry, a decade-long collaborative innovation network between hospitals and biomedical enterprises in China was established and analyzed through social network analysis. The results revealed that the overall levels of collaborative innovation network density, collaborative frequency, and network connectivity were significantly low, especially in less-developed regions. In terms of actors with higher degree centrality, hospitals accounted for the majority, whereas a biomedical enterprise in Shenzhen had the highest degree centrality. Organizations in underdeveloped and northwest regions and small players were more likely to implement collaborative innovation. In conclusion, a collaborative innovation network between hospitals and biomedical enterprises in China demonstrated high dispersion and poor development levels. Stimulating organizations' initiatives for collaborative innovation may enhance quality and quantity of such innovation. Policy support and economic investments, strategic collaborative help, and resource and partnership optimization, especially for small players and in less-developed and northwest regions, should be encouraged to enhance collaborative innovation between hospitals and the biomedical industry in China and other similar countries or regions.
医院与生物医学企业间的协同创新对确保双方发展取得突破至关重要。本研究探讨了中国医院与生物医学企业协同创新的关联主体的结构特征及其主要作用。利用国内医疗行业的共同所有专利数据,通过社会网络分析,构建并分析了中国医院与生物医学企业长达十年的协同创新网络。研究结果表明,整体协同创新网络密度、协同频率和网络连通性水平均显著较低,欠发达地区的情况尤其如此。在具有较高度数中心性的主体中,医院占据多数,而深圳的一家生物医学企业则具有最高的度数中心性。欠发达和西北地区的组织以及小型参与者更倾向于开展协同创新。总之,中国医院与生物医学企业间的协同创新网络呈现出高度分散且发展水平较低的特征。激发组织协同创新的积极性可能会提高协同创新的质量和数量。应鼓励政策支持和经济投入、战略协作帮助以及资源和伙伴关系优化,特别是针对小型参与者和欠发达及西北地区,以加强中国乃至其他类似国家或地区的医院与生物医学产业间的协同创新。
相似文献
Environ Sci Pollut Res Int. 2022-8
Zhonghua Wei Chang Wai Ke Za Zhi. 2020-6-25
Int J Environ Res Public Health. 2020-10-13
Environ Geochem Health. 2022-9
Zhongguo Zhong Yao Za Zhi. 2015-3
Front Public Health. 2023
引用本文的文献
Front Pharmacol. 2025-5-30
本文引用的文献
Front Psychol. 2023-9-14
J Shanghai Jiaotong Univ Sci. 2022-12-26
Health Soc Care Community. 2022-11
Med J Islam Repub Iran. 2021-12-31
Arch Osteoporos. 2021-4-20